Crossmark

Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities

Crossref DOI link: https://doi.org/10.1007/s00262-018-2242-9

Published Online: 2018-09-11

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Weber, Alexander N. R. https://orcid.org/0000-0002-8627-7056
Cardona Gloria, Yamel

Çınar, Özcan

Reinhardt, H. Christian

Pezzutto, Antonio

Wolz, Olaf-Oliver
Funding

Funding for this research was provided by:

Deutsche Forschungsgemeinschaft (SFB 685 “Immunotherapy”)

Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg (Juniorprofessoren-Programm)

Medizinischen Fakultät, Eberhard Karls Universität Tübingen (DE) (Fortüne Junior Grant)

Medizinischen Fakultät, Eberhard Karls Universität Tübingen

Eberhard Karls Universität Tübingen
License Information

Text and Data Mining valid from 2018-09-11
More Information

Article History

Received: 1 May 2018

Accepted: 5 September 2018

First Online: 11 September 2018

Compliance with ethical standards

:

: OOW and AW are named inventors on a patent for the immunotherapeutic exploitation of L265P mutations. The authors declare that there are no other potential conflicts of interest.